Fmoc-L-Cys(Npys)-OH, Boc-L-Cys(Npys)-OH, H-L-Cys(Npys)-OH and other special protective amino acids were used. Due to their high cost, there are too many disadvantages to form disulfide bonds on the solid phase resin and it is difficult to control. Using low-priced H-L-Cys-OH as the synthetic raw material for the final formation of intermolecular disulfide bonds, several simple oxidation methods were used in the liquid phase to obtain a high-purity solution of veracaptide peptide. The reaction was not only accomplished in a homogeneous phase but was also greatly reduced and controlled in dose.
Application of veracatide
Veracatide is a novel CalcimimeticAgent developed by intravenous administration in patients with chronic kidney disease (CKD) who are undergoing hemodialysis (CKD). AMG416 binds to and activates calcium-sensing receptors on the parathyroid gland, resulting in a decrease in parathyroid hormone realization (PTH) levels. It holds great promise as a new drug for effective treatment of secondary hyperparathyroidism. The FDA’s approval of the new calcium-mimicking veracaltide for the treatment of secondary hyperparathyroidism in adults undergoing hemodialysis is the first FDA approval of a drug for the treatment of secondary hyperparathyroidism in dialysis patients in nearly 12 years. PTH levels are significantly decreased in hemodialysis patients with moderate to severe hyperparathyroidism after vilacatide treatment. In contrast, veracatide was superior to placebo and no less effective than cinacalcet.
Post time: Sep-30-2024